Gemini Therapeutics Inc

-0.20 (-7.66%)
Other Pre-Announcement

Gemini Therapeutics Q3 Loss Per Share $0.43

Published: 11/15/2021 12:19 GMT
Gemini Therapeutics Inc (GMTX) - Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update.
Q3 Loss per Share $0.43.
Expect to Provide Six-month Update From Gem103 Regatta Study by Year-end.
Scheduled to Meet With FDA in Q4 2021 and Expect to Initiate Late-stage Trial for Gem103 in Patients With Ga in Q1 2022.